

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,496	01/11/2001	Bernard Delobel	199463US/XPC	1391
22850	7590 03/14/2002			
OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY			EXAMINER	
			COLLINS, CYNTHIA E	
ARLINGTO	, VA 22202		ART UNIT	PAPER NUMBER
			1638	7
			DATE MAILED: 03/14/2002	/

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
. Office Action Summary		09/674,496	DELOBEL ET AL.			
		Examiner	Art Unit			
		Cynthia Collins	1638			
Th MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status 1\⊠	Responsive to communication(s) filed on 11 J	January 2001				
1)⊠ 2a)⊟		is action is non-final.				
3)□	,		rosecution as to the merits is			
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>13-26</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
•	Claim(s) is/are objected to.					
,	Claim(s) <u>13-26</u> are subject to restriction and/or	election requirement.				
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) ☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) 🔲 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)			

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01)

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Applicants are reminded that nucleotide sequences encoding different proteins, and the amino acid sequences they encode, are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute **independent** and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, or the assertion that the sequences are not patentably distinct, each such nucleotide and amino acid sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention.

Group I, claim(s) 13-20, drawn to a method of protecting a plant from insects by treating a plant with a composition comprising a polypeptide. If Group I is elected, restriction to a single amino acid sequence is also required under 35 USC 121. Therefore, if Group I is elected, election of one amino acid sequence is also required.

BEST AVAILABLE COPY

Application/Control Number: 09/674,496 Page 3

Art Unit: 1638

Group II, claim(s) 21-26, drawn to a method of protecting a plant from insects by transforming a plant with a polynucleotide. If Group II is elected, restriction to a single amino acid sequence is also required under 35 USC 121. Therefore, if Group II is elected, election of one amino acid sequence is also required.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The method of treating a plant with a composition comprising a polypeptide of Group I and the method of transforming a plant with a polynucleotide of Group II require the use of molecules that do not have a common structural element, and are therefore not linked by a special technical feature. Furthermore, since a polypeptide having a sequence formula of  $X_1C$   $X_2C$   $X_3C$   $X_4C$   $X_5C$   $X_6C$   $X_7$  is obvious or anticipated over HIGGINS et al. (Journal of Biological Chemistry, 25 August 1986, Vol. 261, No. 24, pages 11124-11130, Applicant's Search Report), a polypeptide having a sequence formula of  $X_1C$   $X_2C$   $X_3C$   $X_4C$   $X_5C$   $X_6C$   $X_7$  does not constitute a special technical feature as defined by PCT Rule 13.2, because it does not define a contribution over the prior art.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the

BEST AVAILABLE COTY

Application/Control Number: 09/674,496

Art Unit: 1638

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Remarks

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Cynthia Collins whose telephone number is (703) 605-1210.

The examiner can normally be reached on Monday-Friday 8:45 AM -5:15 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Amy Nelson can be reached on (703) 306-3218. The fax phone numbers for the

organization where this application or proceeding is assigned are (703) 308-4242 for regular

communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is (703) 308-0196.

CC

March 12, 2002

PHUONG T. BUI

PRIMARY EXAMINER

Page 4